Volume 2 Supplement 1

18th International Symposium on Intensive Care and Emergency Medicine

Open Access

Continuous infusion of propofol for sedation of pediatric patients following open-heart surgery

  • A Darwish1,
  • S Mousa1,
  • B Afrane1,
  • M El-Barbary1 and
  • Z Halees1
Critical Care19982(Suppl 1):P056

DOI: 10.1186/cc186

Published: 1 March 1998


The aim of this study was to prospectively evaluate safety and efficacy of propofol infusion as an alternative sedative agent in children with open-heart surgery.


Twenty-nine pediatric patients with complex congenital lesions, aged between 4 and 48 months, who underwent open-heart surgery, received propofol infusion as sedation after midazolam infusion was ineffective. The effective sedative dose of propofol was between 1.5 and 7.0 mg/kg per h (median 3 mg/kg per h). Measurement of heart rate (HR) electrocardiogram (ECG), blood pressure (BP), arterial blood gas (ABG) including pH, bicarbonate (HCO3), partial carbon dioxide pressure (PCO2), and blood oxygen saturation (PO2); and blood chemistry including liver function tests (LFTs), triglycerides (TG), and total bilirubin (TB), were all done prior to and during propofol therapy.


After 10–288 h of propofol infusion (median 74 h), no statistically significant differences were found in the parameters measured except a decrease in median HR with attendant decrease in BP, and an increase in median TG.


Continuous sedation with propofol is a safe and effective, alternative agent for sedation of infants and children after surgical repair of compex congenital heart disease.



Change in median values

P values

HR (beats/min)



BP (mmHg)



Triglyceride (mmol/l)



Authors’ Affiliations

King Faisal Specialist Hospital and Research Center


© Current Science Ltd 1998